NO975367L - Nye varianter av apolipoprotein A-I - Google Patents

Nye varianter av apolipoprotein A-I

Info

Publication number
NO975367L
NO975367L NO975367A NO975367A NO975367L NO 975367 L NO975367 L NO 975367L NO 975367 A NO975367 A NO 975367A NO 975367 A NO975367 A NO 975367A NO 975367 L NO975367 L NO 975367L
Authority
NO
Norway
Prior art keywords
apolipoprotein
new variants
variants
new
Prior art date
Application number
NO975367A
Other languages
English (en)
Norwegian (no)
Other versions
NO975367D0 (no
Inventor
Gerd Assmann
Patrick Benoit
Eric Bruckert
Patrice Denefle
Nicolas Duverger
Jean-Charles Fruchart
Gerald Luc
Gerard Turpin
Harald Funke
Original Assignee
Rhone Poulenc Rorer Sa
Pasteur Institut
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Pasteur Institut, Univ Paris Curie filed Critical Rhone Poulenc Rorer Sa
Publication of NO975367L publication Critical patent/NO975367L/no
Publication of NO975367D0 publication Critical patent/NO975367D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO975367A 1995-05-22 1997-11-21 Nye varianter av apolipoprotein A-I NO975367D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9506061A FR2734568B1 (fr) 1995-05-22 1995-05-22 Nouveaux variants de l'apolipoproteine
PCT/FR1996/000747 WO1996037608A1 (fr) 1995-05-22 1996-05-20 Nouveaux variants de l'apolipoproteine a-i

Publications (2)

Publication Number Publication Date
NO975367L true NO975367L (no) 1997-11-21
NO975367D0 NO975367D0 (no) 1997-11-21

Family

ID=9479241

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975367A NO975367D0 (no) 1995-05-22 1997-11-21 Nye varianter av apolipoprotein A-I

Country Status (16)

Country Link
EP (1) EP0827538A1 (sk)
JP (1) JPH11505712A (sk)
KR (1) KR19990021828A (sk)
AU (1) AU717202B2 (sk)
BR (1) BR9608813A (sk)
CA (1) CA2218759A1 (sk)
CZ (1) CZ291376B6 (sk)
FR (1) FR2734568B1 (sk)
HU (1) HUP9802926A3 (sk)
IL (1) IL118336A0 (sk)
MX (1) MX9708727A (sk)
NO (1) NO975367D0 (sk)
SK (1) SK156397A3 (sk)
TW (1) TW434260B (sk)
WO (1) WO1996037608A1 (sk)
ZA (1) ZA964097B (sk)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
CA2402772A1 (en) * 2000-03-13 2001-09-20 Amgen Inc. Apolipoprotein-a-i regulation of t-cell signalling
CA2428114C (en) 2000-11-10 2013-07-23 Proteopharma Aps Apolipoprotein analogues
WO2003026492A2 (en) 2001-09-28 2003-04-03 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
BR0310099A (pt) 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
JP4777873B2 (ja) 2003-02-14 2011-09-21 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 親油性薬物送達ビヒクルおよびこれらの使用方法
WO2005097206A2 (en) 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
WO2006012632A2 (en) * 2004-07-23 2006-02-02 Xencor, Inc. Apolipoprotein a-1 derivatives with altered immunogenicity
KR100725642B1 (ko) * 2006-01-20 2007-06-07 충남대학교산학협력단 저밀도 지단백질에 대해 항산화성을 갖는 펩타이드
WO2007137400A1 (en) 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Method and compound for the treatment of valvular stenosis
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
US8153606B2 (en) * 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
SI2396017T1 (sl) 2009-02-16 2015-12-31 Cerenis Therapeutics Holding Sa Mimika apolipoproteina A-1
RU2017126088A (ru) 2011-02-07 2019-01-31 Серени Терапеутикс Холдинг С.А. Липопротеиновые комплексы и их получение и применения

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
IL118336A0 (en) 1996-09-12
FR2734568A1 (fr) 1996-11-29
BR9608813A (pt) 1999-02-17
ZA964097B (en) 1996-12-06
HUP9802926A3 (en) 2001-08-28
HUP9802926A2 (hu) 1999-03-29
SK156397A3 (en) 1998-07-08
WO1996037608A1 (fr) 1996-11-28
FR2734568B1 (fr) 1997-06-20
AU5904896A (en) 1996-12-11
EP0827538A1 (fr) 1998-03-11
TW434260B (en) 2001-05-16
CZ291376B6 (cs) 2003-02-12
JPH11505712A (ja) 1999-05-25
CA2218759A1 (fr) 1996-11-28
NO975367D0 (no) 1997-11-21
CZ367197A3 (cs) 1998-03-18
KR19990021828A (ko) 1999-03-25
MX9708727A (es) 1997-12-31
AU717202B2 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
NO975367D0 (no) Nye varianter av apolipoprotein A-I
NO982809L (no) Prolegemidler av tombin-inhibitorer
DE69623302D1 (de) Sektionsfräsung von bohrlöchern
BR9609797A (pt) Inibição de expressão de gene
NO975159D0 (no) Fremgangsmåte for kontroll av biologisk nedbrytning
DE69634998D1 (de) Kontrolle von Kanten
BR9609726A (pt) Inibição de expressão de gene
FI971784A (fi) Apolipoproteiini B-synteesin estäjiä
EE9700093A (et) Apolipoproteiin-B sünteesi inhiibitorid
DE69622933D1 (de) Prodrugs von Paclitaxel-Derivaten
NO940912D0 (no) Rensing av kuldemedium
FR2731885B1 (fr) Installation d'etageres demontables
NO973203L (no) Nye anvendelser av lysozymdimerer
DE69605202D1 (de) Herstellung von alpha-tocopherol
DE69623986D1 (de) Herstellung von Allomelanin
FI942576A0 (fi) Behandling av plasma
NO974995D0 (no) Estere av karbapenemer
NO974966D0 (no) Nye anvendelser av heptafluorpropan
FI942238A (fi) Furoimidatsolijohdannaisten asymmetrinen hydraus
NO974994D0 (no) Estere av karbapenemer
KR970048178U (ko) 텔레비전의 의사스테레오신호 제어장치
KR970011853U (ko) 새로운 형태의 메리야스
FI954927A0 (fi) Foerfarande foer eliminering av utslaepp i innerluft och anordning haerfoer
KR970020819U (ko) 식기세척기용 화장판의 간격조절구조
FI954671A0 (fi) Foerfarande foer bearbetning speciellt av trae utan saogspaonsrester och motsvarande anordning

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application